CancerNetwork® Face-Off

This Cancer Network FACE-OFF program explores the evolving role of BCMA-targeted therapies in the management of relapsed/refractory multiple myeloma (R/R MM) through a dynamic combination of data presentations, expert debate, and case-based discussion. Moderated by Dr. Shambavi Richard, the program features two expert teams who review pivotal clinical trial and real-world evidence evaluating BCMA-directed CAR-T cell therapies and bispecific antibodies, including emerging data on efficacy, safety, patient selection, and treatment sequencing. Faculty members, including Dr. Prashant Kapoor, Dr. Ridhi Gupta, Dr. Mansi Shah, Dr. Gurbakhash Kaur, Dr. Harsh Parmar, and Dr. Cesar Rodriguez, debate controversial topics such as CAR-T versus bispecific antibodies in earlier lines of therapy, whether meaningful differences exist among BCMA bispecific agents, and the future role of these therapies as treatment paradigms evolve. Through practical patient cases, the panel also discusses referral timing, access challenges, bridging strategies, toxicity management, sequencing after prior BCMA exposure, and the importance of individualized treatment decisions to optimize outcomes for patients with relapsed/refractory multiple myeloma.

Cancer Network's FACE-OFF program brings together leading multiple myeloma experts in a debate-style educational discussion focused on one of the most important questions in contemporary relapsed/refractory multiple myeloma (RRMM) management: how clinicians are integrating BCMA-directed CAR T-cell therapy and bispecific antibody-based approaches earlier in the treatment paradigm. Through a combination of data-driven presentations, moderated debates, and case-based discussions, faculty review emerging evidence from pivotal clinical trials, real-world studies, and long-term outcomes analyses to examine treatment selection, sequencing strategies, safety management, referral pathways, and practical implementation considerations. The program highlights differing expert perspectives on the benefits and challenges associated with these highly active immune-based therapies while exploring how patient characteristics, disease biology, treatment accessibility, toxicity considerations, and real-world logistics influence individualized decision-making in second-line and earlier-relapse RRMM.

Optimizing Frontline Treatment Strategies for the Management of EGFRm NSCLC

Expert panelists face off over the latest frontline trial data and real-world evidence to debate optimal treatment selection in advanced hepatocellular carcinoma.

Panelists discuss how to optimally integrate CAR T-cell therapy into second-line treatment for diffuse large B-cell lymphoma through a competitive, team-based format. The debates highlight real-world updates presented at the American Society of Hematology Annual Meeting 2025, explores evolving sequencing strategies versus salvage chemotherapy and transplant, and examines patient selection, referral timing, and outpatient delivery considerations. The program concludes with case-based analysis to translate emerging evidence into practical decision-making for community oncology practice.

Panelists examine evolving second-line treatment strategies for relapsed/refractory large B-cell lymphoma, highlighting key trial updates, real-world evidence, and practical decision-making considerations. The discussion reviews long-term findings from the TRANSFORM and ZUMA-7 studies alongside emerging real-world data on CAR T utilization, outcomes, and access. Faculty also debate optimal treatment sequencing and delivery models before applying these insights to real-world patient scenarios.

Experts discuss a dynamic and multifaceted debate on frontline and subsequent treatment strategies for EGFR-mutant non–small cell lung cancer (NSCLC), addressing the promise and challenges of combination therapies, central nervous system efficacy, long-term tolerability, sequencing complexities, and patient-centered decision-making in complex clinical scenarios to optimize outcomes amid evolving evidence and real-world considerations.

Panelists discuss how to optimize treatment approaches for patients with lower-risk myelodysplastic syndrome through a competitive debate format covering luspatercept vs erythropoiesis-stimulating agents as first-line therapy, management of super-responders, timing of treatment initiation, and real-world evidence from recent clinical trials including COMMANDS, MEDALIST, and IMerge.

Panelists discuss various aspects of lower-risk myelodysplastic syndromes, including trial results on erythropoiesis-stimulating agent timing and novel agents like luspatercept and imetelstat, treatment sequencing and timing debates, personalized approaches based on erythropoietin levels, and complex case management balancing immediate symptom relief with long-term strategies.

Amer Zeidan, MBBS; Catherine Lai, MD; Bart Scott, MD; Andrew Brunner, MD; Jonathan Abbas, MD; Akriti Jain, MD; Mohamed Hegazi, MD; Somedeb Ball, MBBS; and Salman Fazal, MD, examine critical clinical decisions in myelodysplastic syndrome management, including optimal sequencing of erythropoiesis-stimulating agents vs luspatercept, dosing strategies, and efficacy data from pivotal trials such as MEDALIST, IMerge, and ELEMENT-MDS, which demonstrate improvements in transfusion burden and hemoglobin levels.

Panelists discuss how emerging therapies like CC-486, venetoclax, and menin inhibitors are reshaping treatment strategies for relapsed and refractory acute myeloid leukemia while debating the role of posttransplant maintenance and personalized approaches based on genetic mutations such as NPM1 and TP53.

Experts examine diverse aspects of bispecific antibody therapies in relapsed/refractory multiple myeloma, including clinical trial results, combination strategies, dosing considerations, sequencing with CAR T-cell therapy, prophylactic measures, outpatient administration, and implementation in community settings, to optimize patient outcomes and treatment approaches.

Experts examine cutting-edge treatments, clinical trial results, and personalized approaches for managing relapsed/refractory multiple myeloma, focusing on novel therapies like CAR T-cells, bispecific antibodies, and their optimal sequencing to improve patient outcomes.

Experts from University of California San Diego and City of Hope discuss and debate treatment practices for patients with advanced non–small cell lung cancer.

Experts from Northwestern University and the University of Chicago present data and debate treatment practices in the non–small cell lung cancer space.

A panel of experts analyzed and discussed phase 2&3 trial findings on efficacy and safety of emerging targeted therapies such as ADCs, bispecific, and CAR-T cells for relapsed/ refractory blood cancers.

A panel of experts analyzed and discussed phase 2&3 trial findings on efficacy and safety of emerging targeted therapies such as ADCs, bispecific, and CAR-T cells for relapsed/ refractory blood cancers.

A team of experts discuss multiple topics related to non-small cell lung cancer.

A panel of experts discussing treatment for ALK positive for non-small cell malignancies.

Two teams from Karmanos Cancer Institute and Cleveland Clinic debate and discuss recent data in the chronic myeloid leukemia treatment landscape.

Two teams from Karmanos Cancer Institute and Cleveland Clinic debate and discuss recent data in the multiple myeloma treatment landscape.

Experts from the Fred Hutchinson Cancer Center and City of Hope form two teams and go head-to-head in this review of the latest datasets in the multiple myeloma treatment landscape.

Experts from the Fred Hutchinson Cancer Center and City of Hope form two teams and go head-to-head in this review of the latest datasets in the chronic myeloid leukemia treatment landscape.

Two teams from leading institutions, UT Southwestern and the Mayo Clinic, go head-to-head to review the latest datasets in chronic myeloid leukemia management.

Two teams from leading institutions, UT Southwestern and the Mayo Clinic, go head-to-head to review the latest datasets in multiple myeloma management.